Glaucoma Stocks List

Glaucoma Stocks Recent News

Date Stock Title
May 3 LXRX Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call
May 3 OCUL Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
May 3 LXRX Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
May 2 LXRX Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
May 2 LXRX Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
May 2 LXRX Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $1.13M misses by $0.27M
May 2 LXRX Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 1 LXRX Lexicon Pharmaceuticals Q1 2024 Earnings Preview
May 1 BLCO Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript
May 1 STAA STAAR Surgical Company's (NASDAQ:STAA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
May 1 BLCO Bausch & Lomb Corp (BLCO) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Net Loss Widening
May 1 OCUL Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
May 1 BLCO Bausch + Lomb GAAP EPS of -$0.48, revenue of $1.1B
May 1 STAA STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
May 1 BLCO Bausch + Lomb Announces First-Quarter 2024 Results
Apr 30 BLCO Bausch + Lomb Q1 2024 Earnings Preview
Apr 29 ACAD Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
Apr 29 LXRX Lexicon Pharmaceuticals announces retirement of CEO Lonnel Coats
Apr 29 CANF Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
Apr 29 LXRX Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
Glaucoma

Glaucoma is a group of eye diseases which result in damage to the optic nerve and vision loss. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Peripheral vision may begin to decrease followed by central vision resulting in blindness if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent.Risk factors for glaucoma include increased pressure in the eye, a family history of the condition, and high blood pressure. For eye pressures a value of greater than 21 mmHg or 2.8 kPa is often used with higher pressures leading to a greater risk. However, some may have high eye pressure for years and never develop damage. Conversely, optic nerve damage may occur with normal pressure, known as normal-tension glaucoma. The mechanism of open-angle glaucoma is believed to be slow exit of aqueous humor through the trabecular meshwork while in closed-angle glaucoma the iris blocks the trabecular meshwork. Diagnosis is by a dilated eye examination. Often the optic nerve shows an abnormal amount of cupping.If treated early it is possible to slow or stop the progression of disease with medication, laser treatment, or surgery. The goal of these treatments is to decrease eye pressure. A number of different classes of glaucoma medication are available. Laser treatments may be effective in both open-angle and closed-angle glaucoma. A number of types of glaucoma surgeries may be used in people who do not respond sufficiently to other measures. Treatment of closed-angle glaucoma is a medical emergency.About 6 to 67 million people have glaucoma globally. The disease affects about 2 million people in the United States. It occurs more commonly among older people. Closed-angle glaucoma is more common in women. Glaucoma has been called the "silent thief of sight" because the loss of vision usually occurs slowly over a long period of time. Worldwide, glaucoma is the second-leading cause of blindness after cataracts. The word "glaucoma" is from Ancient Greek glaukos which means blue, green, or gray. In English, the word was used as early as 1587 but did not become commonly used until after 1850, when the development of the ophthalmoscope allowed people to see the optic nerve damage.

Browse All Tags